Physician profile
Jorge Leal
NPI 1376559468
$1,531.20
in general payments reported to CMS, 2019-2025
15 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $72.19 · 2021: $12.67 · 2022: $279 · 2023: $131 · 2024: $40.92 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $231.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $223.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $185.02 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $170.66 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Abbott Laboratories | $152.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $150.13 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $73.54 | 2019-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $67.35 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.35 | 2022 | |
| Arbor Pharmaceuticals, INC. | $55.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $54.11 | 2019-2023 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $49.26 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.32 | 2024 | Rexulti |
| Abbvie INC. | $17.52 | 2023 | |
| Novo Nordisk INC | $16.45 | 2025 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Leal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.